Similar articles

• LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?

  Keizman D, Eisenberger MA. Keizman D, et al. Oncology (Williston Park). 2009 Jun;23(7):631-2. Oncology (Williston Park). 2009. PMID: 19626831 No abstract available.
• The role of LHRH antagonists in the treatment of prostate cancer.

  Crawford ED, Hou AH. Crawford ED, et al. Oncology (Williston Park). 2009 Jun;23(7):626-30. Oncology (Williston Park). 2009. PMID: 19626830 Review.
• Important considerations in LHRH antagonist therapy for prostate cancer.

  Garnick MB. Garnick MB. Oncology (Williston Park). 2009 Jun;23(7):636-7. Oncology (Williston Park). 2009. PMID: 19626833 No abstract available.
• Pharmacotherapy for prostate cancer: the role of hormonal treatment.

  Shahani R, Fleshner NE, Zlotta AR. Shahani R, et al. Discov Med. 2007 Aug;7(39):118-24. Discov Med. 2007. PMID: 18093474
• Multiple intracrine hormonal targets in the prostate: opportunities and challenges.

  Labrie F. Labrie F. BJU Int. 2007 Jul;100 Suppl 2:48-51. doi: 10.1111/j.1464-410X.2007.06955.x. BJU Int. 2007. PMID: 17594360 Review. No abstract available.